Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Vienna - Delayed Quote EUR

Bristol-Myers Squibb Company (BMYS.VI)

Compare
51.01
-3.77
(-6.88%)
At close: April 4 at 5:32:17 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
48,300,000
48,300,000
45,006,000
46,159,000
46,385,000
Cost of Revenue
13,968,000
13,968,000
10,693,000
10,137,000
9,940,000
Gross Profit
34,332,000
34,332,000
34,313,000
36,022,000
36,445,000
Operating Expense
28,445,000
28,445,000
26,118,000
26,918,000
27,908,000
Operating Income
5,887,000
5,887,000
8,195,000
9,104,000
8,537,000
Net Non Operating Interest Income Expense
-1,947,000
-1,947,000
-1,166,000
-1,232,000
-1,334,000
Other Income Expense
-12,319,000
-12,319,000
1,411,000
-159,000
895,000
Pretax Income
-8,379,000
-8,379,000
8,440,000
7,713,000
8,098,000
Tax Provision
554,000
554,000
400,000
1,368,000
1,084,000
Net Income Common Stockholders
-8,948,000
-8,948,000
8,025,000
6,327,000
6,994,000
Diluted NI Available to Com Stockholders
-8,948,000
-8,948,000
8,025,000
6,327,000
6,994,000
Basic EPS
-3.58
-4.41
3.88
2.97
3.25
Diluted EPS
-3.58
-4.41
3.86
2.95
3.12
Basic Average Shares
2,026,250
2,027,000
2,069,000
2,130,000
2,153,000
Diluted Average Shares
2,027,750
2,027,000
2,078,000
2,146,000
2,245,000
Total Expenses
42,413,000
42,413,000
36,811,000
37,055,000
37,848,000
Net Income from Continuing & Discontinued Operation
-8,948,000
-8,948,000
8,025,000
6,327,000
6,994,000
Normalized Income
1,235,100
1,235,100
8,063,120
7,447,103
7,213,999.51
Interest Expense
1,947,000
1,947,000
1,166,000
1,232,000
1,334,000
Net Interest Income
-1,947,000
-1,947,000
-1,166,000
-1,232,000
-1,334,000
EBIT
-6,432,000
-6,432,000
9,606,000
8,945,000
9,432,000
EBITDA
3,168,000
3,168,000
19,366,000
19,221,000
20,118,000
Reconciled Cost of Revenue
13,240,000
13,240,000
9,980,000
9,456,000
9,277,000
Reconciled Depreciation
9,600,000
9,600,000
9,760,000
10,276,000
10,686,000
Net Income from Continuing Operation Net Minority Interest
-8,948,000
-8,948,000
8,025,000
6,327,000
6,994,000
Total Unusual Items Excluding Goodwill
-12,890,000
-12,890,000
-40,000
-1,361,000
-254,000
Total Unusual Items
-12,890,000
-12,890,000
-40,000
-1,361,000
-254,000
Normalized EBITDA
16,058,000
16,058,000
19,406,000
20,582,000
20,372,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,706,900
-2,706,900
-1,880
-240,897
-34,000.49
12/31/2021 - 6/27/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4AB.SG AbbVie Inc
170.34
-7.14%
 
0QAH.IL Merck & Co., Inc.
83.10
-5.14%
 
CUP.F Chugai Pharmaceutical Co., Ltd.
39.36
0.00%
 
6MK.F Merck & Co., Inc.
74.30
-5.35%
 
0QCV.IL AbbVie Inc.
194.50
-4.45%
 
ZEG.F AstraZeneca PLC
126.40
-7.94%
 
4AB.DE AbbVie Inc.
176.56
-4.38%
 
SNW.F Sanofi
93.50
-6.23%
 
DSKYF Daiichi Sankyo Company, Limited
23.63
0.00%
 
0QOK.IL Roche Holding AG
264.00
-5.09%